NCT04383197

Exercise and GLP-1 RA on Insulin Secretion

Effects of 12 Weeks of Endurance Exercise Training Alone or in Combination With Glucagon Like Peptide 1 Receptor Agonist (GLP-1 RA) Treatment on Insulin Secretory Capacity in Type 2 Diabetes

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: University of Copenhagen · Academic / Other
• Sex: All
• Age: 40 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effect of endurance exercise on insulin secretory capacity, alone or in addition to treatment with the glucagon-like-peptide receptor agonist semaglutide, in patients with type 2 diabetes.

Detailed description

The effects of endurance exercise alone or in addition to treatment with glucagon-like- peptide receptor agonists on insulin secretory capacity, will be determined in patients with type 2 diabetes. Included patients will be randomized to either 12 weeks of endurance exercise training 3 times a week or therapeutical treatment with semaglutide for 3 months followed by 12 weeks of endurance exercise training 3 times a week. Insulin secretory capacity will be determined by hyperglycemic clamp method before and after.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
BEHAVIORAL	Endurance exercise training	Ergometer cycling at 70 % of VO2 max, 45 minutes, 3 times a week
DRUG	Semaglutide	3 months of therapeutic treatment with semaglutide

Timeline

• Start date: 2019-12-10
• Primary completion: 2021-08-01
• Completion: 2022-08-01
• First posted: 2020-05-12
• Last updated: 2021-02-11

Locations

1 site across 1 country: Denmark